The Situation: The Hong Kong Stock Exchange’s failure to recognize that investors are able to evaluate biotech companies in the pre-revenue stages, and its consequent refusal to list those companies for trading, is viewed by...more
1/9/2018
/ China ,
Disclosure Requirements ,
Foreign Investment ,
Fund-raising ,
Hong Kong ,
Hong Kong Stock Exchange ,
Listing Rules ,
Listing Standards ,
Research and Development ,
Revenue Growth ,
Technology Sector